CDI-00355-2018.R2

Original Article

**A cohort study of local excision followed by adjuvant therapy incorporating a contact x- ray brachytherapy boost instead of radical resection in 180 patients with rectal cancer**

**Authors:** F. M. Smith FRCSI1, D. M. Pritchard FRCP1,2, H. Wong PhD3, K. Whitmarsh FRCR3, M. J. Hershman FRCS4, and A. Sun Myint FRCR2,3

1. Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK

2. Institute of Translational Medicine, University of Liverpool, Liverpool, UK

3. Clatterbridge Cancer Centre, Bebington, Wirral, UK

4. New Cross Hospital, Wolverhampton, UK

**Short running head:** *Contact radiation after local excision*

**Keywords:** rectal cancer; radiotherapy, chemotherapy, local excision, ‘watch and wait’

Correspondence and requests for reprints to:

Mr Fraser M. Smith

Department of Surgery,

The Royal Liverpool and Broadgreen University Hospitals NHS Trust,

Liverpool,

L7 1XP

Tel: 0151 706 2000

Fax: 0151 706 2345

E-mail: fassiefern@hotmail.com

**Category:** Original article

**Word Count:** 2957

**Source of Support:** This study was unfunded and there are no relevant financial relationships

**Presentations at meetings:** This manuscript was presented as a podium presentation at the American Society of Colon and Rectal Surgeons (Tripartite Meeting), Seattle, Washington, June 10-14, 2017

**Structured Abstract (229 words)**

**Aim**

Recent data have suggested near-equivalent oncological results when treating early rectal cancer by local excision followed by radio +/- chemotherapy rather than salvage radical surgery. The aim of this retrospective study was to assess the use of contact x-ray brachytherapy within this paradigm.

**Methods**

All patients had undergone local excision and were referred to our radiotherapy centre for treatment with contact x-ray brachytherapy. Postoperative (chemo) radiotherapy was also given in their local hospital in most cases. Variables assessed were local excision method, post-operative therapy received, follow-up duration, disease-free survival, salvage surgery and stoma-free survival.

**Results**

In total 180 patients with a median age of 70 (range 36-99) years were assessed. Following local excision, pT stages were pT1=131(72%), pT2=44(26%), pT3=5(2%). All patients received contact x-ray brachytherapy boosting at our centre and in addition 110 received chemoradiotherapy and 60 received radiotherapy alone.After a median follow up of 36 months (range 6-48), 169 patients (94%) remained free of local recurrence. Of the 11 patients with local recurrence (3 isolated nodal), 5 underwent salvage abdomino-perineal resection. 8 patients developed distant disease of whom 5 underwent metastasis surgery. At last included follow-up 173 (96%) patients were free of all disease and 170 (94%) were stoma free.

**Conclusions**

Contact therapy can be offered in addition to external beam radio (+/-chemo) therapy instead of radical surgery as follow-on treatment after local excision of early rectal cancer. This combination can provide equivalent outcomes to radical surgery.  ~~high rates of organ preservation and stoma free survival which are equivalent to those expected after radical surgery.~~ The added value of contact therapy should be formally assessed in a clinical trial.

**What does this paper add to the literature?**

In this series, following local excision of early rectal cancers, radical surgery could be avoided in over 94% of patients by treating the retained rectum with a contact x-ray brachytherapy boost, usually in combination with external beam (chemo) radiation. After all salvage treatments 96% were disease-free and 94% were stoma-free.

**Introduction**

The introduction of bowel cancer screening programmes internationally has increased the number of patients who are being diagnosed with early rectal cancer.1,2 Although traditionally radical surgery incorporating total mesorectal excision has been recommended as standard treatment for rectal cancer, the risks and functional sequelae of this approach have generated interest in alternative, less invasive approaches, especially for patients with early stage disease.3-7

It is now accepted that local excision alone for rectal cancers staged as T1sm1 R0 can constitute definitive treatment as the risk of local relapse is very low.3,6 In clinical practice, however, because of limitations in pre-operative staging, after initial local excision, tumours are often found to be at a more advanced stage or have adverse features such as involved or R1 margins, or lympho-vascular invasion when examined pathologically.7-9 In addition, rectal cancer is increasingly being diagnosed after excision of polyps that were endoscopically thought to be benign.6 In these scenarios, because of the high chance of finding no further disease after radical surgery (with all of its incumbent risks and the possibility of a stoma), it can be unclear what represents the best follow-on strategy. As such, patients are often offered radical surgery as a ‘fail-safe’.

The aim of this study was to analyse the outcome of a large number of patients who had been diagnosed with rectal cancer after local excision and who were referred to our institution for treatment with contact x-ray brachytherapy (CXB). Patients who were referred usually also received post-operative long course chemoradiotherapy (LCCRT) or external beam radiotherapy (EBRT). Patients have been referred for attempted organ preservation to our centre since 1993 because of its unique position (until recently) within the UK of being able to offer contact x-ray brachytherapy.10-12 This technique allows very high doses of radiation to be delivered very precisely transanally to the site of the local excision and can be given in addition to conventional external beam radiotherapy.10-12 The technique uses low energy x-rays 50kVp which are confined to the aperture of the treatment applicator, therefore uninvolved portions of the rectum can be completely excluded from the boost volume. In addition, treatment delivery time is approximately 60 seconds, it is relatively comfortable for the patient and is generally given on an outpatient basis. Broadly, the cohort of patients referred to our centre for CXB was either frail/elderly/comorbid patients, or patients who were offered an APR but wished to avoid a colostomy.

The aim of this study was to analyse the oncological outcomes from the series of patients treated in this manner at our institution.

**Methods**

*Initial patient selection and exclusions*

All patients referred for CXB after prior local rectal cancer excision from January 2003 to November 2012 were identified from a prospectively maintained institutional database. In order to assess at least 2 years follow up data were censored at November 2014. Referrals were received from UK clinicians for patients who had already undergone local excision and were felt to be at high risk of local recurrence and were either 1. Medically unfit or elderly or 2. Fit enough for surgery but had refused completion surgery at the time of informed consent. On these grounds specific ethical approval was not deemed to be necessary by our trust but this study was approved by the local audit committee (No 01-02/26).

Importantly, the patients analysed in this series were referred from surgeons all across the UK and the high proportion of adverse features in this group is reflective of our centre being the main national referral centre for organ preservation rather than this being a consecutive series of patients who had been treated locally with poor surgical or endoscopic technique. Prior to treatment, all patients had been diagnosed with biopsy-proven adenocarcinoma of the rectum, had undergone full endoscopic and radiological staging, and had been discussed in a local colorectal cancer multi-disciplinary team meeting. Local T and N staging was determined using pelvic MRI except in those with cardiac pacemakers. All patients were free of distant metastases as determined by a baseline contrast-enhanced CT scan of the chest, abdomen and pelvis. Patients agreed to treatment after informed consent and counselling. Usually patients who required EBRT or LCCRT had this delivered locally and attended our institution solely for CXB.

Patients who had developed local recurrence following prior local excision and patients that had received prior radiation therapy followed by local excision were excluded from this study.

*CXB dosage schedule*

In the majority of cases, CXB was administered as an outpatient treatment every 2 weeks. At each visit 30Gy of 50KV x-rays, targeted directly on the scar from local excision, was given under direct vision through a stainless rigid applicator between 2.2, 2.5 and 3 cm diameter. The standard dosage schedule was 60Gy in 2 fractions over two weeks.

*Surveillance protocol*

The surveillance protocol that was used was identical to our “watch and wait” protocol that has been described in detail in previous publications from our unit.12, 13 In brief, the most intensive monitoring was undertaken within the first 2 years after therapy, when the risk of recurrence was highest. If any active recurrence of tumour was suspected or detected, the patient was restaged and offered surgical salvage, provided no inoperable distant metastases were detected and they were fit and agreeable to the surgical procedure.

*Data integrity and statistical analysis*

As data had been accrued over many years, we commissioned an external, independent validator to ensure accuracy and integrity of our data. This process identified that 94% of initial entries were accurate. All identified inaccuracies were corrected. All data were analysed using SPSS Version 21 (IBM, UK). The Chi-Squared test was used for all categorical data analysis. Binary logistic regression was used for multivariate analyses. Survival analyses were performed using Kaplan-Meier estimation and Cox proportional hazard regression models.

**Results**

Our database identified two hundred and four patients for whom CXB had been delivered after a prior local excision between 2003-2012. Twenty four of these patients were excluded because: 5 received palliative CXB, 9 had multiple primary cancer types, 4 had additional HDR brachytherapy, five were lost to follow-up and one patient was from overseas. After exclusions one hundred and eighty patients were therefore suitable for inclusion into the present study. This group constituted 113 males and 67 females with a median age of 70 years (range 36-99 years). 148 (82%) had a performance status of 0 or 1.

Local excision was performed by: endoscopic mucosal resection (EMR) n=57(32%); Transanal resection (TAR) n=64(35%); and Transanal Endoscopic Micro Surgery (TEMS) n=59(33%). (Table 1a) Pathological stages at the time of referral to our centre were pT1=131(72%), pT2=44(26%), pT3=5(2%) (Table 1). A more detailed breakdown of pathological characteristics for patients with T1 tumours prior to receiving CXB can be found in table 2.

Tumours were located at an average of 5.9cm from the anal verge and had a mean size of 2.6cm on histopathological analysis and the vast majority (92%) of patients were clinically lymph node negative. Only 6 were lymph node positive and nodal stage was unknown in 8.

Initial histology showed R0 resection in 69, R1 in 60, and R2 in 1.In fifty patients resection status was not known (RX) as the tumour was removed piecemeal.

110 had LCCRT (of which 2 had to stop early because of toxicity). Of these, the majority had 45Gy in 25 Fractions over 5 weeks. A further 60 patients who were not fit for chemotherapy had had EBRTalone, the majority of whom had 25Gy in 5 fractions over 5 days or its biological equivalent.

**Oncological outcomes**

The median follow up was 36 months (range 6-48 months) from the time of the last given treatment. Only 4 patients had less than 24 months follow up because they died within this period from comorbidities. At the end of the study period, only 15 patients (9%) had evidence of any form of disease regrowth. These patients, along with their subsequent treatments are detailed in table 3. Eight patients developed endoluminal local recurrence within a median of 15.6 months (range 10-55 months), three developed an isolated regional nodal recurrence, and eight (4%) developed distant metastases. Five of the 11 patients who had local regrowths underwent salvage surgery with an abdomino-perineal excision (4 were R0 resections). Within this group, 3 of the 7 patients with no evidence of distant metastases underwent radical salvage. Five patients with distant disease underwent resection of metastases. Five patients with disease recurrence were not fit for salvage surgery and were managed by best supportive care.

Because of the small number of events there was insufficient power to determine if specific high risk features such as R1, tumour diameter or lymphovascular invasion had an effect on local recurrence.

Using Kaplan-Meier survival estimation, the local recurrence-free survival of the group was modelled at 95% (CI 92-99%) at 3 years and overall survival was modelled at 91% and 83% at 3 and 5 years respectively (Figs 1a and b).

**Treatment-related toxicity**

The only toxicity that was formally assessed in the study group was per rectum bleeding as from experience this is by far the most common side effect. This was experienced in 43 (24%) patients and was measured using the Common Terminology Criteria for Adverse Events Score (Version 4).14 29 of these 43 were grade 3 and 24 required argon plasma coagulation.

**Summary of outcomes from our group**

At the end of all treatments (including surgery for metastatic disease and local salvage) 173 (96%) patients were free of disease and 170 (94%) were stoma free. Bleeding was the main adverse effect and required argon plasma coagulation in 24 (13%) of patients.

**Discussion**

Currently, radical completion surgery is recommended as the optimal oncological treatment for patients with adverse tumour features after local excision of early rectal cancer.3-6 Our data, however, derived from patients who were referred to our centre because they either chose not to, or were too unfit to have a radical resection in this setting, have shown local regrowth rates of only 4% for T1 tumours and only 7% for T2 tumours after the addition of a contact boost. when contact x-ray brachytherapy was delivered to the local excision scar in addition to post-operative radio +/- chemotherapy as an alternative to radical surgery. These data highlight that empirical radical surgery can safely be avoided in many patients who have been diagnosed with early rectal cancer and have undergone local excision.

There are already several published reports of managing patients with adverse features after local excision with radiotherapy +/- chemotherapy instead of radical surgery. A recent meta-analysis by Borstlap et al assessed data from studies which included at least ten patients with pT1/pT2 adenocarcinomas removed trans-anally followed by adjuvant chemoradiotherapy.15 This study showed that the weighted average for local recurrence was 10% (range 4-21%) for T1 tumours and 15% (range 11-21%) for T2 tumours. This study also assessed the outcomes after radical completion TME and found that the weighted average of local control was6% (range 3%-15%) and 10% (range 4%-22%) for T1 and T2 tumours respectively. There are, however, only limited data reporting outcomes of the addition of a contact boost to this regimen.10-12,16-18

In the ‘watch and wait’ literature, there is now mounting evidence that the addition of a contact x-ray brachytherapy boost to external beam (chemo) radiotherapy both increases the rate of complete clinical response and decreases the rate of local regrowth in the setting of rectal cancer13, 16-18 This benefit is likely to be derived from the known dose-response effect of increasing the dose of radiotherapy to induce tumour cell death. The benefit of contact therapy in this paradigm is that it uses low energy x-rays that only penetrate a few millimetres into the rectal wall and thus do not affect surrounding normal tissues. Our data, suggest that a similar benefit is likely to be achieved in the setting of patients who have undergone local excision of early rectal cancer and wish to avoid surgery. While we do not have a control group with which to directly compare our data, we note that our data are equivalent to the very best outcomes reported in a recent meta-analysis using postoperative adjuvant treatment without contact therapy. Here, the weighted average for local recurrence for T1 disease was 10% and 15% for T2 disease.15 Our data also compare favourably to the weighted average local regrowth rates for equivalent disease stages after radical salvage surgery.15 Importantly, by adding external beam (chemo) radiation to the contact boost we still treat mesorectal nodal disease which we believe explains our favourable outcomes in patients of more advanced tumour stage. It still remains to be clarified in exactly what circumstances contact therapy may be beneficial in an organ preserving approach. R1 resection is a definite indication in our centre. We do sometimes offer treatment for R0 resections, if LVI/poor differentiation or T2, as we know that most local recurrences are at the mucosal level. The contact boost can deliver very large additional doses to a depth of around 1cm to the excision scar and so theoretically reduce local regrowth by sterilising cells in this area. We propose that the main role of EBRT is to treat the mesorectal lymph nodes. We appreciate that the true benefit of adding contact therapy to EBRT alone and the degree to which it benefitted patients with R0 resections would be best investigated in a clinical trial. We also propose that in tandem there is increased awareness amongst clinicians of the importance of achieving R0 resection and avoiding piecemeal resection of large polyps as part of good practice.

We believe that our data are therefore important because increasingly in surgical practice there is a ‘trade-off’ between oncological risk and the actual risks of surgery itself. Colorectal cancer is known to be a disease of the elderly with approximately 70% of the patients who develop rectal cancer being over the age of 65. The age of highest likelihood of developing rectal cancer is 80.19 Increasing data show that intermediate term mortality after radical surgery for rectal cancer can be considerable in elderly patients when compared to baseline mortality.19-22 As such, the excellent local control seen in our patient cohort questions the need for radical surgery being offered as the “safer option”.

Similarly, we believe our data are important because of the changing patterns of disease with increasing prevalence of early stage disease. Data from a review of 31,223 patients diagnosed with rectal cancer and who underwent a major abdominal procedure within the NHS in England found that 32% of patients were Dukes stage A. This same review found that 40% of these patients that received radical surgery for Dukes A rectal cancer were above the age of 80 years.23

Even for younger patients who are fit and well, in order for consent for radical surgery to be valid, they must also understand the risks of the surgical intervention being offered and any alternative treatments available to them. In this setting, some patients may wish to avoid a temporary or permanent stoma or the risks of pelvic nerve damage incurred by radical surgery and so may opt for chemoradiotherapy as a definitive treatment on that basis. Several recent publications have highlighted that patients are not always fully informed about the different options available to them and often feel that they were not involved in choosing the treatment that they ultimately received.24-26

There are several accepted weaknesses of our study. The first is that it was not part of a randomised clinical trial; it therefore lacks a control group, and includes a disparate patient cohort. In some respects though, it was not possible to generate a control group from within our own data because all patients were referred specifically to receive CXB in an attempt to attain optimal local control. CXB has been the standard of care in our unit for over 20 years and so it was not delivered as part of a trial. We believe, however, that an advantage to our data is that we report “real-world” outcomes from a large and unique study group which in turn can be broadly compared to the numerous reports of management without CXB.13 Notwithstanding this, however, we do accept that definitive proof of the benefits of CXB in addition to post-operative external beam radiotherapy +/- chemotherapy would be best assessed in a prospective, randomised setting.

A further weakness is that we did not formally assess toxicity induced by external beam radiation or chemotherapy for the patients in our dataset because most patients had this treatment delivered at their referring local centres. Our data showed, however, that all patients received the full dosage of CXB and there was no immediate toxicity from it. We also did not formally assess rectal function in our study group, nor did we specifically assess late toxicity other than PR bleeding. Weare, however, in the process of assessing rectal function in patients who are currently undergoing treatment.Despite this lack of data, the side effects of CXB have recently undergone intensive study by NICE and the technique has been formally deemed safe.27

A final criticism of our data is that aspects of the pathological analysis could be improved on. For example analyses were not standardised as they were done in local referring centres which is a potential source of bias. Our data also lack full details of submucosal invasion status for a proportion of T1 tumours (Table 2). We are unable to give clarity as to why submucosal invasion depth was not recorded on a case-by-case basis, but we note that many of the T1 lesions were attributed to this stage after a prior EMR polypectomy where it is not possible to accurately measure the degree of submucosal invasion. In addition, tumours with positive margins following local excision were often low and TEMS excision of the scar may not have been deemed possible or the patients may have been unfit for or refused surgery**.** Lastlyour data had limited reporting of adverse pathological features such as lymphovascular invasion and tumour budding.

**Conclusion**

Current guidelines accept radical surgery as the standard of care following local excision of early rectal cancer staged >T1sm1. The data we present highlight the oncological safety of non-operative management of such patients that have received a contact x-ray brachytherapy boost in combination with external beam radiotherapy +/- chemotherapy within our institution. Importantly, our data show equivalent local control to radical completion surgery as reported by a recent systematic review on the subject and better than average results than with chemo-radiotherapy alone.13 These data suggest that all patients should be made aware of the alternative treatment options for early rectal cancer at the time of informed consent and their views should be taken into account when final treatment decisions are made. A randomised trial which includes CXB in addition to external beam radiotherapy would help to formally clarify its role in this area.

**References**

1. UK Colorectal Cancer Screening Pilot Group. Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom. *BMJ* 2004; 329:133.
2. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. *Lancet* 2002; 359:1291–1300.
3. Williams JG, Pullan RD, Hill J et al Management of the malignant colorectal polyp: ACPGBI position statement *Colorectal Dis.* 2013; 15 Suppl 2:1-38.
4. Wasif N, Etzioni D, Maggard MA, Tomlinson JS, Ko CY. Trends, patterns, and outcomes in the management of malignant colonic polyps in the general population of the United States. *Cancer*. 2011; 117:931–937.
5. Gill MD, Rutter MD, Holtham SJ. Management and short-term outcome of malignant colorectal polyps in the north of England. *Colorectal Dis.* 2013; 15:169-176.
6. Morino M, Risio M, Bach S et al Early rectal cancer: the European Association for Endoscopic Surgery (EAES) clinical consensus conference. *Surg Endosc.* 2015; 29:755-773.
7. Smith FM, Waldron D, Winter DC. Rectum-conserving surgery in the era of chemoradiotherapy. *Br J Surg.* 2010; 12:1752-1764.
8. Patel RK, Sayers AE, Kumar P, Khulusi S, Razack A, Hunter IA. The role of endorectal ultrasound and magnetic resonance imaging in the management of early rectal lesions in a tertiary center. *Clin Colorectal Cancer.* 2014; 13:245-250.
9. Waage JE, Bach SP, Pfeffer F, Leh S, Havre RF, Ødegaard S, Baatrup G. Combined endorectal ultrasonography and strain elastography for the staging of early rectal cancer. *Colorectal Dis.* 2015; 17:50-56.
10. Sun Myint A, Grieve RJ, McDonald AC, et al. Combined Modality Treatment of Early Rectal Cancer - the UK Experience. *Clinical Oncology*. 2007; 19:674-681.
11. Hershman MJ, Myint AS, Makin CA. Multi-modality approach in curative local treatment of early rectal carcinomas. *Colorectal Dis.* 2003; 5:445-450.
12. Smith FM, Al-Amin A, Wright A, Berry J, Nicoll JJ, Sun Myint A. Contact radiotherapy boost in association with 'watch and wait' for rectal cancer: initial experience and outcomes from a shared programme between a district general hospital network and a regional oncology centre. *Colorectal Dis.* 2016; 18:861-870.
13. Sun Myint A, Smith FM, Gollins S, Wong H, Rao C, Whitmarsh K, Sripadam R, Rooney P, Hershman M, Pritchard DM. Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience. *Int J Radiat Oncol Biol Phys.* 2018 Mar 1;100(3):565-573.
14. https://www.eortc.be/services/doc/ctc/CTCAE\_4.03\_2010-06-14\_QuickReference\_5x7.pdf Accessed 10th Feb 2018
15. Borstlap WA, Coeymans TJ, Tanis PJ et al. Meta-analysis of oncological outcomes after local excision of pT1-2 rectal cancer requiring adjuvant (chemo)radiotherapy or completion surgery. *Br J Surg*. 2016; 103:1105-1116.
16. Dhadda AS, Martin A, Killeen S, Hunter IA. Organ Preservation Using Contact Radiotherapy for Early Rectal Cancer: Outcomes of Patients Treated at a Single Centre in the UK. *Clin Oncol* (R Coll Radiol). 2017; 29:198-204.
17. Frin AC, Evesque L, Gal J, Benezery K et al. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. *Eur J Cancer*. 2017; 72:124-136.
18. Gérard JP, Chapet O, Romestaing P, Favrel V, Barbet N, Mornex F. Local excision and adjuvant radiotherapy for rectal adenocarcinoma T1-2 N0. Gastroenterol Clin Biol. 2000 Apr;24(4):430-5
19. Rutten H., Den Dulk M., Lemmens V., Van De, Velde C., Marijnen C. Controversies of total mesorectal excision for rectal cancer in elderly patients. *Lancet Oncol* 2008; 9: 494–450.
20. Mamidanna R, Almoudaris AM, Faiz O.Is 30-day mortality an appropriate measure of risk in elderly patients undergoing elective colorectal resection? *Colorectal Dis*. 2012; 14:1175-1182.
21. Mamidanna R, Eid-Arimoku L, Almoudaris et al Poor 1-year survival in elderly patients undergoing non-elective colorectal resection. *Dis Colon Rectum.* 2012; 55: 788-796.
22. Finlayson E, Zhao S, Varma MG. Outcomes after rectal cancer surgery in elderly nursing home residents. *Dis Colon Rectum*. 2012; 55:1229-1235.
23. E Morris, P Quirke, J D Thomas, et al. Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? *Gut*2008; 57(12):1690-1697.
24. Kunneman M, Marijnen CA, Baas-Thijssen MC et al. Considering patient values and treatment preferences enhances patient involvement in rectal cancer treatment decision making. [*Radiother Oncol.*](https://www.ncbi.nlm.nih.gov/pubmed/26372343) 2015; 117:338-342.
25. Kunneman M, Stiggelbout AM, Marijnen CA, Pieterse AH. Probabilities of benefit and harms of preoperative radiotherapy for rectal cancer: What do radiation oncologists tell and what do patients understand? *Patient Educ Couns*. 2015; 98:1092-1098.
26. Tyler Ellis C, Charlton ME, Stitzenberg KB. Patient-Reported Roles, Preferences, and Expectations Regarding Treatment of Stage I Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. *Dis Colon Rectum.* 2016;59: 907-915.
27. https://www.nice.org.uk/guidance/ipg532/chapter/1-Recommendations (Accessed 2nd August 2017)

**Table 1:** Breakdown of local excision method for rectal cancers prior to CXB +/- (chemo) radiotherapy. EMR – Endoscopic Mucosal Resection. TAR – Trans-anal resection with retractors TEMS – Transanal Endoscopic Micro Surgery

|  |  |  |  |
| --- | --- | --- | --- |
| **T Stage (Group)** | **SURGERY\_TYPE** | **R margin** | **Number.** |
| **pT1** | **EMR** | R0 | 8 |
|  |  | R1 | 21 |
|  |  | RX | 17 |
|  | **EMR Total** |  | **46** |
|  | **TAR** | R0 | 9 |
|  |  | R1 | 18 |
|  |  | RX | 17 |
|  | **TAR Total** |  | **44** |
|  | **TEMS** | R0 | 31 |
|  |  | R1 | 5 |
|  |  | RX | 5 |
|  | **TEMS Total** |  | **41** |
| **pT1 Total** |  |  | **131** |
| **pT2** | **EMR** | R0 | 1 |
|  |  | R1 | 4 |
|  |  | R2 | 1 |
|  |  | RX | 4 |
|  | **EMR Total** |  | **10** |
|  | **TAR** | R0 | 5 |
|  |  | R1 | 8 |
|  |  | RX | 6 |
|  | **TAR Total** |  | **19** |
|  | **TEMS** | R0 | 13 |
|  |  | R1 | 1 |
|  |  | RX | 1 |
|  | **TEMS Total** |  | **15** |
| **pT2 Total** |  |  | **44** |
| **pT3** | **EMR** | R1 | 1 |
|  | **EMR Total** |  | **1** |
|  | **TAR** | R1 | 1 |
|  | **TAR Total** |  | **1** |
|  | **TEMS** | R0 | 2 |
|  |  | R1 | 1 |
|  | **TEMS Total** |  | **3** |
| **pT3 Total** |  |  | **5** |
| **Grand Total** |  |  | **180** |

**Table 2:** Pathological features of pT1 rectal cancers prior to receiving CXB

|  |  |  |  |
| --- | --- | --- | --- |
| **T1** | **Differentiation** | **R Status** | **Total** |
| **Depth Invasion** | **R0** | **R1** | **RX** |
| **SM1** | Well |  | 1 | 1 | 2 |
|  | Moderate | 1 | 3 |  | 4 |
|  | Not Known | 1 | 1 |  | 2 |
| **SM1 Total** |  | **2** | **5** | **1** | **8** |
| **SM2** | Well | 1 |  | 1 | 2 |
|  | Moderate | 5 | 6 | 1 | 12 |
|  | Poor |  | 2 |  | 2 |
|  | Not Known |  |  | 1 | 1 |
| **SM2 Total** |  | **6** | **8** | **3** | **17** |
| **SM3** | Well | 2 |  |  | 2 |
|  | Moderate | 16 | 7 | 1 | 24 |
|  | Poor |  | 1 |  | 1 |
|  | Not Known | 4 |  | 1 | 5 |
| **SM3 Total** |  | **22** | **8** | **2** | **32** |
| **Not known** | Well | 3 | 3 | 6 | 12 |
|  | Moderate | 14 | 15 | 20 | 49 |
|  | Poor |  | 1 | 1 | 2 |
|  | Not Known | 1 | 4 | 6 | 11 |
| **Not known Total** |  | **18** | **23** | **33** | **74** |
| **Grand Total** |  | **48** | **44** | **39** | **131** |

**Table 3:** Details of the 15 patients that had disease recurrence. EMR – Endoscopic Mucosal Resection; TAR – Trans-anal resection with retractors; TEMS – Transanal Endoscopic Micro Surgery; RT – External beam radiotherapy; APR – Abdominoperineal Excision

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Number** | **T Stage** | **N Stage** | **Surgery** | **R margin** | **Chemotherapy** | **RT Dose (Gy)/#** | **End of CXB to relapse (months)** | **Site of recurrence** | **Treatment for recurrence** |
| 1 | pT2 | cN0 | TAR | RX | No Chemo | No EBRT | 15.84 | Local | Palliative treatment & Symptom control |
| 2 | pT1 | cN0 | TAR | RX | No Chemo | 45/25 | 19.82 | Local & Distant | APR |
| 3 | pT1 | cN0 | EMR | Rx | Raltitrexed | 45/25 | 7.92 | Local & Distant | APR |
| 4 | pT2 | cN0 | TEMS | R0 | Capecitabine | 45/20 | 11.18 | Local | Palliative treatment & Symptom control |
| 5 | pT1 | cN0 | TAR | R1 | Capecitabine | 45/25 | 33.89 | Local | APR |
| 6 | pT2 | cN0 | TEMS | R0 | 5 Fluorouracil | 45/25 | 18.01 | Local | APR |
| 7 | pT1 | cN0 | TAR | RX | Capecitabine | 50.40/28 | 10.09 | Local | APR |
| 8 | pT1 | cN1 | TAR | R0 | No chemo | 45/25 | 55.46 | Local | Palliative treatment & Symptom control |
| 9 | pT1 | cN0 | TEMS | R1 | 5 Fluorouracil | 45/25 | 16.77 | Distant | Lung surgery |
| 10 | pT1 | cN0 | TEMS | R0 | Capecitabine | 45/25 | 6.31 | Distant | Liver surgery |
| 11 | pT1 | cN0 | EMR | R1 | No chemo | 45/20 | 38.86 | Regional Node & Distant | Palliative treatment & Symptom control |
| 12 | pT1 | cN0 | TAR | R1 | Capecitabine | 45/25 | 23.34 | Distant | Lung surgery |
| 13 | pT1 | cN0 | EMR | R0 | Capecitabine | 45/25 | 20.74 | Distant | Lung surgery |
| 14 | pT2 | cN0 | TAR | Rx | No chemo | 20/4 | 64.56 | Regional node | Palliative treatment & Symptom control |
| 15 | pT1 | cN0 | TAR | RX | 5 Fluorouracil | 45/25 | 48.55 | Regional Node & Distant | Liver surgery |

**Figures 1 a +b:** Kaplan-Meier survival curves showing (a) Estimated 3 year local recurrence-free survival and (b) Estimated overall 3 and 5 year survival.

